JOP20210008A1 - أنواع أبيراز مذابة، وطرق لاستخدامها - Google Patents
أنواع أبيراز مذابة، وطرق لاستخدامهاInfo
- Publication number
- JOP20210008A1 JOP20210008A1 JOP/2021/0008A JOP20210008A JOP20210008A1 JO P20210008 A1 JOP20210008 A1 JO P20210008A1 JO P20210008 A JOP20210008 A JO P20210008A JO P20210008 A1 JOP20210008 A1 JO P20210008A1
- Authority
- JO
- Jordan
- Prior art keywords
- solubilized
- methods
- apyrases
- preventing
- design
- Prior art date
Links
- 102000007347 Apyrase Human genes 0.000 title abstract 2
- 108010007730 Apyrase Proteins 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
يتعلق الاختراع الحالي بتصميم واستخدام علاجي لبولي ببتيدات أبيراز، وتركيبات صيدلانية، واستخدامات علاجية، وطرق مفيدة في الوقاية من وعلاج تلف الأنسجة.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18184269 | 2018-07-18 | ||
PCT/IB2019/056117 WO2020016804A1 (en) | 2018-07-18 | 2019-07-17 | Solubilized apyrases, methods and use |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210008A1 true JOP20210008A1 (ar) | 2021-01-12 |
Family
ID=62985993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0008A JOP20210008A1 (ar) | 2018-07-18 | 2019-07-17 | أنواع أبيراز مذابة، وطرق لاستخدامها |
Country Status (26)
Country | Link |
---|---|
US (1) | US20220356455A1 (ar) |
EP (1) | EP3824079A1 (ar) |
JP (2) | JP7425784B2 (ar) |
KR (1) | KR20210035806A (ar) |
CN (1) | CN112424346A (ar) |
AR (1) | AR115790A1 (ar) |
AU (1) | AU2019306821B2 (ar) |
BR (1) | BR112021000586A2 (ar) |
CA (1) | CA3103684A1 (ar) |
CL (1) | CL2021000129A1 (ar) |
CO (1) | CO2021000210A2 (ar) |
CR (1) | CR20210021A (ar) |
CU (1) | CU20210008A7 (ar) |
EA (1) | EA202190057A1 (ar) |
EC (1) | ECSP21002804A (ar) |
IL (1) | IL280191A (ar) |
JO (1) | JOP20210008A1 (ar) |
MA (1) | MA53177A (ar) |
MX (1) | MX2021000542A (ar) |
PE (1) | PE20210185A1 (ar) |
PH (1) | PH12021550122A1 (ar) |
SG (1) | SG11202011776RA (ar) |
TW (1) | TW202016299A (ar) |
UY (1) | UY38299A (ar) |
WO (1) | WO2020016804A1 (ar) |
ZA (1) | ZA202007187B (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021243173A1 (en) * | 2020-05-28 | 2021-12-02 | Charm Sciences, Inc. | Methods and assemblies for sample analysis |
WO2024023746A1 (en) | 2022-07-29 | 2024-02-01 | Novartis Ag | Improved production of cd39 variants |
TW202404627A (zh) | 2022-07-29 | 2024-02-01 | 瑞士商諾華公司 | 使用cd39、重組cd39用於急性器官損傷的治療 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6425699A (en) | 1998-10-16 | 2000-05-08 | Cornell Research Foundation Inc. | Methods of inhibiting platelet activation and recruitment |
US20020002277A1 (en) * | 1998-10-16 | 2002-01-03 | Maliszewski Charles Richard | Inhibitors of platelet activation and recruitment |
US6867177B2 (en) | 1999-08-13 | 2005-03-15 | The Trustees Of Columbia University In The City Of New York | CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders |
US7247300B1 (en) | 2002-11-07 | 2007-07-24 | Apt Therapeutics, Inc. | Therapeutic use of soluble CD39L3 |
WO2006096989A2 (en) | 2005-03-17 | 2006-09-21 | National Research Council Of Canada | Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression |
WO2011088231A1 (en) * | 2010-01-13 | 2011-07-21 | Apt Therapeutics, Inc. | Apyrase therapy for bleeding conditions |
DK3083677T3 (da) | 2013-12-20 | 2019-11-25 | Novartis Ag | Hidtil ukendte eukaryote celler og fremgangsmåder til rekombinant ekspression af et produkt af interesse |
RU2720525C2 (ru) | 2013-12-20 | 2020-04-30 | Новартис Аг | Новые эукариотические клетки и способы их получения для рекомбинантной экспрессии представляющего интерес продукта |
-
2019
- 2019-07-15 UY UY0001038299A patent/UY38299A/es unknown
- 2019-07-16 TW TW108125140A patent/TW202016299A/zh unknown
- 2019-07-16 AR ARP190102009A patent/AR115790A1/es unknown
- 2019-07-17 CN CN201980047594.2A patent/CN112424346A/zh active Pending
- 2019-07-17 PE PE2021000054A patent/PE20210185A1/es unknown
- 2019-07-17 CR CR20210021A patent/CR20210021A/es unknown
- 2019-07-17 US US17/261,533 patent/US20220356455A1/en active Pending
- 2019-07-17 AU AU2019306821A patent/AU2019306821B2/en active Active
- 2019-07-17 BR BR112021000586-2A patent/BR112021000586A2/pt unknown
- 2019-07-17 CA CA3103684A patent/CA3103684A1/en active Pending
- 2019-07-17 WO PCT/IB2019/056117 patent/WO2020016804A1/en active Application Filing
- 2019-07-17 MA MA053177A patent/MA53177A/fr unknown
- 2019-07-17 EP EP19769879.8A patent/EP3824079A1/en active Pending
- 2019-07-17 KR KR1020217001187A patent/KR20210035806A/ko unknown
- 2019-07-17 EA EA202190057A patent/EA202190057A1/ru unknown
- 2019-07-17 SG SG11202011776RA patent/SG11202011776RA/en unknown
- 2019-07-17 MX MX2021000542A patent/MX2021000542A/es unknown
- 2019-07-17 JO JOP/2021/0008A patent/JOP20210008A1/ar unknown
- 2019-07-17 CU CU2021000008A patent/CU20210008A7/es unknown
- 2019-07-17 JP JP2021502432A patent/JP7425784B2/ja active Active
-
2020
- 2020-11-18 ZA ZA2020/07187A patent/ZA202007187B/en unknown
-
2021
- 2021-01-14 IL IL280191A patent/IL280191A/en unknown
- 2021-01-14 EC ECSENADI20212804A patent/ECSP21002804A/es unknown
- 2021-01-14 CO CONC2021/0000210A patent/CO2021000210A2/es unknown
- 2021-01-15 PH PH12021550122A patent/PH12021550122A1/en unknown
- 2021-01-15 CL CL2021000129A patent/CL2021000129A1/es unknown
-
2023
- 2023-11-14 JP JP2023193640A patent/JP2024023297A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3103684A1 (en) | 2020-01-23 |
AU2019306821A1 (en) | 2020-12-24 |
CO2021000210A2 (es) | 2021-01-18 |
JP2024023297A (ja) | 2024-02-21 |
BR112021000586A2 (pt) | 2021-04-06 |
KR20210035806A (ko) | 2021-04-01 |
AR115790A1 (es) | 2021-02-24 |
CU20210008A7 (es) | 2021-08-06 |
JP7425784B2 (ja) | 2024-01-31 |
US20220356455A1 (en) | 2022-11-10 |
PE20210185A1 (es) | 2021-02-02 |
EP3824079A1 (en) | 2021-05-26 |
SG11202011776RA (en) | 2021-02-25 |
WO2020016804A1 (en) | 2020-01-23 |
CR20210021A (es) | 2021-03-23 |
CL2021000129A1 (es) | 2021-08-20 |
MA53177A (fr) | 2021-05-26 |
ZA202007187B (en) | 2022-06-29 |
PH12021550122A1 (en) | 2021-09-27 |
CN112424346A (zh) | 2021-02-26 |
JP2021529550A (ja) | 2021-11-04 |
MX2021000542A (es) | 2021-03-29 |
ECSP21002804A (es) | 2021-04-29 |
TW202016299A (zh) | 2020-05-01 |
UY38299A (es) | 2020-02-28 |
AU2019306821B2 (en) | 2022-09-29 |
EA202190057A1 (ru) | 2021-08-24 |
IL280191A (en) | 2021-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
PH12015501983B1 (en) | Peptides and compositions for treatment of joint damage | |
PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
PH12019502646A1 (en) | Pyrazole magl inhibitors | |
MX2020006191A (es) | Bacteriocinas terapeuticas. | |
MD3768284T2 (ro) | Compoziţii de entrecoccus flagellin pentru utilizare în terapie | |
MX2020003762A (es) | Composiciones cosmeticas y metodo para tratar la piel. | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
MX2020001632A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2019010218A (es) | Derivados de pirazol como inhibidores de bromodominio. | |
MX2017013879A (es) | Composiciones que comprenden anakinra. | |
MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
MX2019000006A (es) | Composiciones para el tratamiento de estrias y ulceras de origen isquemico. | |
MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
MX2021002444A (es) | Compuestos y metodos para el tratamiento de infecciones fungicas. | |
PH12020500404A1 (en) | Composition for controlled ovarian stimulation | |
NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease | |
MX2020013684A (es) | Formulaciones/composiciones que comprenden ibrutinib. | |
WO2018211323A8 (en) | Heterocyclic compounds for the treatment of disease | |
PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
EA202092204A1 (ru) | Композиции | |
MX2020002812A (es) | Abx196 para usarse en el tratamiento del cancer de vejiga. | |
MX2015009505A (es) | Actividad antimicrobiana "in vitro" de la combinacion de peptidos antibiocidas de alacran con antibioticos de uso comun. | |
MY173606A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease |